ContraFect Corporation Культура компании

Dr. Steven C. Gilman, also known as Steve, Ph.D., is Scientific Advisor of Spero Therapeutics, Inc. Dr. Gilman has been the Chief Executive Officer and President of ContraFect Corporation since July 21, 2016 and as its Executive Chairman since May 20, 2015. Dr. Gilman is on Leave of Absence. Dr. Gilman served as an Interim Chief Executive Officer of ContraFect Corporation from March 21, 2016 to July 21, 2016. Dr. Gilman served as the Chief Scientific Officer at Cubist Pharmaceuticals Inc. since February 2008 and served as its Executive Vice President of Research & Development since September 2010. He has more than 28 years of drug research and development experience. He served as a Senior Vice President of Discovery & Non Clinical Development at Cubist Pharmaceuticals Inc. from February 2008 to September 2010. He served as the Chairman of the Board of ActivBiotics, Inc. from May 1, 2007 to February 2008 and also as its Chief Executive Officer from March 2004 to February 2008 and President from March 2004 to May 1, 2007. He served as the Chief Executive Officer and President of ActivBiotics Canada Inc., a subsidiary of ActivBiotics, Inc. While at ActivBiotics, he led the transition of the ActivBiotics from early research/academic stage to focus on advanced product development and commercialization. He served as Vice President and General Manager of Inflammation Franchise of Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation Franchise. He served as Group Director of Pfizer Global Research and Development, where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. He has also held scientific, business and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. He was responsible for pharmaceutical research units at Sterling Winthrop and Wyeth Laboratories in areas including chronic inflammatory diseases, transplant rejection, autoimmune diseases and bacterial infections. He has been a Director of Momenta Pharmaceuticals Inc. since June 22, 2016. He has been an Independent Director of Keryx Biopharmaceuticals Inc. since April 1, 2016, SCYNEXIS, Inc. since February 25, 2015 and Vericel Corporation since January 2015. He has been a Director of ContraFect Corporation since May 20, 2015. He serves on the Biotechnology Advisory Board of Penn State University. He serves on director of the Massachusetts Biotechnology Council and Nextcea, Inc. He serves as a Director of the Northeastern University Drug Discovery Advisory Board. He served as a Director of Inhibikase Therapeutics, Inc. from May 2011 to January 8, 2016. He served as a Director of ActivBiotics, Inc. since March 2004. Dr. Gilman received his B.A. degree from Miami University (Ohio) and his M.S. and Ph.D. degrees in Microbiology from Pennsylvania State University. He completed a Post-Doctoral Research Fellowship in the Department of Immunopathology at the Scripps Clinic and Research Foundation.

Mr. Michael Messinger, CPA has been the Senior Vice President of Finance at ContraFect Corporation since October 01, 2016. Mr. Messinger served as the Vice President of Finance at ContraFect Corporation since November 2012 until October 01, 2016 and served as its Chief Accounting Officer until October 01, 2016. Mr. Messinger has more than 15 years of experience in finance, accounting and forecasting for clinical development. He served as Controller of Coelacanth Corporation prior to his role as Director of Finance for Lexicon Pharmaceuticals, Inc. In this capacity, he was responsible for the financial management of Lexicon's partnership with Symphony Capital, LLC, in addition to coordinating fiscal and program management concerning Lexicon's development programs. He started his career as an auditor at Ernst & Young, LLP. He received his B.B.A degree in accounting from the University of Michigan.

Dr. Cara Cassino M.D., has been the Chief Medical Officer of ContraFect Corporation since September, 2015 and has also been Executive Vice President of Research & Development since October 2015. Dr. Cassino served as the Senior Vice President of Development at ContraFect Corporation since September, 2015 until October 01, 2016. Dr. Cassino served as the Senior Vice President of Global Clinical Development at Forest Laboratories, Inc. (Forest) and served on its R&D Executive Leadership team. She led Forest's clinical development organization which was responsible for a portfolio of more than 35 compounds, (including 7 drugs in the anti-infective space) and was also instrumental in the clinical due diligence process for Forest's $2.9 billion acquisition of Aptalis Pharma and $1.1 billion acquisition of Furiex Pharmaceuticals. Prior to joining Forest, she held a number of senior executive positions at Pfizer, including Global Medical Team Leader of Pfizer's antibacterial franchise which included Zyvox (linezolid) and Medicines Development Group Vice President for Pulmonary Vascular Disease and Rare Disease. Prior to Pfizer, she held positions of increasing responsibility at Boehringer Ingelheim culminating in the role of Executive Medical Director of Boehringer's late stage respiratory franchise in the U.S. She has extensive experience in the design and execution of drug development programs across a broad range of therapeutic areas, with the approval of more than 20 regulatory submissions in the U.S. and globally over the course of her career. Dr. Cassino served as a Member of the academic faculty of Division of Pulmonary and Critical Care Medicine at New York University (NYU) School of Medicine in New York City. Dr. Cassino completed her internship and residency in Internal Medicine at NYU/Bellevue Hospital, followed by fellowship in Pulmonary/Critical Care Medicine at NYU and Mount Sinai Medical Center in New York City. She graduated summa cum laude and Phi Beta Kappa from NYU with a BA in Chemistry and Fine Arts and received her medical degree from NYU.

Mr. Josh Muntner has been Senior Vice President of Business Development at ContraFect Corporation since September 2015. Mr. Muntner served as a Managing Director and Co-Head of Healthcare Investment Banking at Janney Montgomery Scott, where he was responsible for originating and executing equity financing and M&A transactions for the Janney 's life science clients. Prior to Janney, he served as Managing Director at ThinkEquity, where he re-established the ThinkEquity's healthcare banking practice. He spent nine years at Oppenheimer &Co. and its predecessor, CIBC World Markets, after starting his investment banking career at Prudential Securities. He has been involved with a wide range of capital markets and advisory transactions with approximately $11bn in value. He has more than 15 years of healthcare investment banking experience. Mr. Muntner received his MBA from the UCLA Anderson School of Management and a Bachelor of Fine Arts from Carnegie Mellon University.

Mr. Paul Boni has been the Head of Investor Development and Strategy at ContraFect Corporation since August 2015. Mr. Boni served as Global Head of Research Services at Integreon, Inc., where he was in charge of the strategic research business and carried out special project work for its key life science and financial services clients. Mr. Boni joined Integreon's Research Services business from Grail Research following its acquisition by Integreon in 2009. Mr. Boni has over 14 years of experience as an investor, analyst and executive in the biotechnology industry. Previously, Mr. Boni worked as an analyst/portfolio manager at PAW Partners, where he covered healthcare investments. At PAW partners, he was responsible for investments in the healthcare sector, covering biotechnology, health insurance, pharmaceuticals and medical devices. Mr. Boni served as Vice President of Equity Research at Punk, Ziegel and Company (later acquired by Ladenburg Thalmann Financial Services) and also covered biotechnology stocks at Mehta and Isaly (later split into Orbimed Advisors and Mehta Partners). He started his career as an Investment Analyst on Wall Street covering the global biotechnology and pharmaceutical sectors at Mehta and Islay (now Mehta Partners and Orbimed Advisors). He was a sell side analyst and covered the biotechnology sector and also served as Chief Financial Officer at Mojave Therapeutics, a start-up biotechnology company. He has a BS from Harvard College with honors in Biology.